The recent selloff in MedTech stocks, particularly those related to diabetes management, "seems overdone," according to analysts at Citi.MedTech diabetes ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE